Phase III study of adjuvant vaccination with Bec2/bacille calmette-guerin in responding patients with limited-disease small-cell lung cancer (European organisation for research and treatment of cancer 08971-08971B; silva study) Academic Article uri icon

Overview

MeSH Major

  • Adjuvants, Immunologic
  • BCG Vaccine
  • Carcinoma, Small Cell
  • Lung Neoplasms
  • Nerve Tissue Proteins
  • Potassium Channels, Voltage-Gated

abstract

  • Vaccination with Bec2/BCG has no impact on outcome of patients with limited-disease SCLC responding to combined-modality treatment. Vaccination strategies in SCLC may still be warranted using vaccines that produce a better immunologic response.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.17.186

PubMed ID

  • 16192577

Additional Document Info

start page

  • 6854

end page

  • 64

volume

  • 23

number

  • 28